Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Siemens Showcases Broad Portfolio of Infectious Disease Testing Capabilities at ECCMID 2012

Published: Monday, April 16, 2012
Last Updated: Monday, April 16, 2012
Bookmark and Share
Company exhibit featured the latest in liver health, microbiology and molecular diagnostic solutions.

Siemens Healthcare Diagnostics has showcased its broad portfolio of infectious disease testing capabilities¹ — from screening and diagnosis to susceptibility testing, genotyping, therapy selection and monitoring — at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in London. The Siemens solutions on display at ECCMID 2012 reinforced the company's commitment to the development of reliable, high-quality infectious disease diagnostic solutions to help laboratories optimise workflow and enhance operational efficiency.

The exhibit — themed “Innovation. Powered for Infectious Disease Solutions.”— featured innovative products designed to address the current and growing demands of infectious disease testing, including customised workflow options, assays to help clinicians improve patient care, and clinically-validated, expert-based software solutions that support personalised medicine.

“Infectious disease is a leading cause of death worldwide2, making it critical that clinicians have access to diagnostic solutions that provide trustworthy results, which ultimately contribute to optimal patient outcomes,” said Christoph Gauer, PhD, CEO, Molecular and Microbiology Business Segment at Siemens Healthcare Diagnostics. “Visitors to our ECCMID booth learnt how Siemens can help them improve the delivery of vital information healthcare providers require to care for their patients impacted by infectious disease.”

Liver Health Solutions

The Siemens ECCMID exhibit provided a platform to showcase the company’s portfolio of diagnostic solutions for managing liver-disease patients, including routine chemistry tests, hepatitis serology assays, viral load testing and ultrasound systems. A key highlight was the recently launched ADVIA Centaur® ELF™ Test3, the first routine standardised direct biomarker panel for the assessment of liver fibrosis, a leading indicator of chronic liver disease, such as cirrhosis and liver cancer. With results provided in about an hour, the ELF test combines three serum biomarkers—hyaluronic acid (HA), Procollagen III amino terminal peptide (PIIINP) and tissue inhibitor of metalloproteinase 1 (TIMP-1)—which provide a score, shown to correlate to the level of liver fibrosis as assessed by liver biopsy. In an international multi-centre study with a mix of patient groups, the ELF test was clinically validated and found to be accurate to differentiate mild, moderate and severe fibrosis4.

Microbiology Solutions

Attendees also learnt about Siemens’ latest microbiology offerings, including LabPro Connect, a new software solution that consolidates databases for multiple testing systems. The open-system configuration option delivers workstation networking by aggregating LabPro ID/AST data to bench and laboratory office computers, reducing wasted staff time absorbed by visiting different instruments to collect information. LabPro Connect can also be configured as a closed-system without workstation networking.

Also highlighted were microbiology automation and mass spectrometry solutions now available from Siemens as a result of a recently forged strategic partnership with Copan and co-marketing agreement with Bruker Corporation. The Copan Walk-Away Specimen Processor (WASP® instrument)5 offers fully automated bacteriology specimen processing, individualised sample management, utilising familiar streaking patterns, standardises workflow processes and optimises specimen set-up activities to free up staff resources. The Bruker MALDI Biotyper6 provides faster, more accurate and very cost-effective molecular microorganism identification using MALDI-TOF mass spectrometry for proteomic fingerprinting. This technology provides faster TTR, along with outstanding accuracy and sensitivity, to meet the demands of diverse laboratory needs.

Molecular Solutions

Additionally, Siemens’ ECCMID booth included information about the VERSANT® HCV RNA 1.0 Assay, a highly sensitive viral load assay for the VERSANT kPCR Molecular System7. This assay aids in the management of individuals infected with hepatitis C (HCV)—one of the main causes of chronic liver disease worldwide8— who are undergoing antiviral therapy. This assay provides outstanding precision across the dynamic range and 100% specificity with a 95% lower confidence limit of 99.7%, and features technology that is compatible with all HCV genotypes.

Visitors also found out about TRUGENE® HIV-1 GuideLines™ 17.09, the latest interpretive algorithm for HIV-1 drug resistance, which are clinically validated and updated annually by an independent expert panel, as well as the company’s latest tissue preparation and extraction solutions to maximise lab efficiency.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos